Story
Intuit Shares Fall on Weak Outlook; Semtech Climbs on Strong AI Demand

Intuit (INTU) shares fell significantly in after-hours trading Tuesday after the financial software company issued a full-year forecast that fell well short of analyst expectations. The negative reaction overshadowed positive moves from semiconductor firm Semtech (SMTC), which rose on strong earnings fueled by artificial intelligence demand.
Guidance Weighs on Software Stocks
Intuit shares plunged 9% in extended trading. The primary driver was its conservative guidance for fiscal year 2027, which projected full-year earnings per share (EPS) of $22.88–$23.12, missing Wall Street’s $27.30 consensus. The company's revenue forecast of $23.3–$23.5 billion also trailed the expected $23.74 billion, which it attributed to slower growth in its TurboTax unit and ongoing platform restructuring.
Other software companies also faced pressure:
- nCino, Inc. (NCNO), a cloud banking platform, fell 10%. While its Q2 results were in line, its Q3 revenue guidance of $161.25–$163.25 million barely met expectations, sparking investor concerns about elongated sales cycles among its regional banking clients.
- Zoom Video Communications (ZM) stock declined 3.5% despite a modest Q2 earnings beat and a slight increase in its full-year revenue guidance. The move suggests investors are focused on the persistent normalization of growth in its core online business.
Semtech Surges on AI-Driven Beat
AdIn contrast, semiconductor supplier Semtech saw its shares gain 3%. The company reported a strong second-quarter performance, with adjusted EPS of $0.71 on revenue of $341.9 million, easily beating analyst targets.
Growth was propelled by a 64% surge in its AI data center networking segment. Management also issued an optimistic Q3 outlook, projecting revenue of $405–$415 million and EPS of $1.02–$1.08, both well above consensus estimates.
Biotech Firm Spyre Plummets on Trial Results
Spyre Therapeutics (SYRE) experienced the most dramatic move, with its stock plummeting 16%. The biotechnology company announced disappointing topline results from its Phase 2 SKYWAY clinical trial for SPY072, a treatment for rheumatoid arthritis.
According to the announcement, the drug failed to meet its internal efficacy threshold to be advanced as a monotherapy, leading to a sharp sell-off from investors.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.